Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
$4.90
+2.3%
$4.38
$1.58
$7.27
$436.79M-0.61.22 million shs529,953 shs
Owens & Minor, Inc. stock logo
OMI
Owens & Minor
$6.51
-0.2%
$7.42
$6.07
$17.78
$502.54M1.381.14 million shs1.18 million shs
Patterson Companies, Inc. stock logo
PDCO
Patterson Companies
$31.33
$31.26
$19.45
$31.79
$2.77B0.731.26 million shsN/A
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
$5.19
+9.0%
$5.58
$4.32
$14.45
$717.46M1.361.39 million shs1.89 million shs
Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
+1.48%-11.79%-4.39%+51.58%+180.12%
Owens & Minor, Inc. stock logo
OMI
Owens & Minor
-0.99%-5.36%-4.75%-5.36%-62.32%
Patterson Companies, Inc. stock logo
PDCO
Patterson Companies
0.00%0.00%0.00%+0.58%+30.65%
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
+2.15%+5.54%-21.97%-41.31%-55.64%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
3.2639 of 5 stars
3.61.00.00.03.24.21.3
Owens & Minor, Inc. stock logo
OMI
Owens & Minor
4.686 of 5 stars
3.01.00.03.92.83.33.8
Patterson Companies, Inc. stock logo
PDCO
Patterson Companies
1.4779 of 5 stars
1.00.02.51.70.81.72.5
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
2.8177 of 5 stars
3.41.00.00.02.83.31.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
3.13
Buy$9.83100.68% Upside
Owens & Minor, Inc. stock logo
OMI
Owens & Minor
2.00
Hold$12.5092.16% Upside
Patterson Companies, Inc. stock logo
PDCO
Patterson Companies
2.09
Hold$26.57-15.19% Downside
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
2.86
Moderate Buy$32.86533.09% Upside

Current Analyst Ratings Breakdown

Latest OMI, PDCO, VIR, and AMLX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/22/2025
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$14.00 ➝ $14.00
5/14/2025
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$7.00 ➝ $8.00
5/12/2025
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$19.00 ➝ $14.00
5/9/2025
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$12.00 ➝ $16.00
5/7/2025
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeMarket Perform ➝ Outperform$4.00 ➝ $10.00
5/6/2025
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Strong-Buy
4/17/2025
Owens & Minor, Inc. stock logo
OMI
Owens & Minor
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$13.00 ➝ $11.00
4/17/2025
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$28.00 ➝ $21.00
4/7/2025
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Outperform$3.00 ➝ $7.00
3/10/2025
Owens & Minor, Inc. stock logo
OMI
Owens & Minor
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetUnderweight ➝ Underweight$14.00 ➝ $10.00
3/5/2025
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$12.00 ➝ $12.00
(Data available from 5/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
-$1.27M-343.39$0.89 per share5.51$6.42 per share0.76
Owens & Minor, Inc. stock logo
OMI
Owens & Minor
$10.72B0.05$5.20 per share1.25$12.08 per share0.54
Patterson Companies, Inc. stock logo
PDCO
Patterson Companies
$6.51B0.43$3.42 per share9.17$11.18 per share2.80
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
$14.30M50.16N/AN/A$11.82 per share0.44
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
$49.27M-$3.11N/AN/AN/AN/A-36.97%-29.61%8/14/2025 (Estimated)
Owens & Minor, Inc. stock logo
OMI
Owens & Minor
-$41.30M-$4.75N/A3.700.20-0.46%14.60%2.51%8/1/2025 (Estimated)
Patterson Companies, Inc. stock logo
PDCO
Patterson Companies
$185.93M$1.5418.3212.842.712.37%19.77%6.66%6/17/2025 (Estimated)
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
-$615.06M-$4.22N/AN/AN/A-678.40%-36.71%-31.00%7/30/2025 (Estimated)

Latest OMI, PDCO, VIR, and AMLX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
6/17/2025Q4 2025
Patterson Companies, Inc. stock logo
PDCO
Patterson Companies
$0.92N/AN/AN/AN/AN/A
5/10/2025Q1 2025
Owens & Minor, Inc. stock logo
OMI
Owens & Minor
$0.20$0.23+$0.03N/AN/AN/A
5/8/2025Q1 2025
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
-$0.45-$0.42+$0.03-$0.42N/AN/A
5/8/2025Q1 2025
Owens & Minor, Inc. stock logo
OMI
Owens & Minor
$0.20$0.23+$0.03-$0.32$2.66 billion$2.63 billion
5/7/2025Q1 2025
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
-$0.83-$0.88-$0.05-$0.88$8.59 million$3.03 million
3/4/2025Q4 2024
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
-$0.49-$0.55-$0.06-$0.55N/A($0.67) million
2/28/2025Q4 2024
Owens & Minor, Inc. stock logo
OMI
Owens & Minor
$0.53$0.55+$0.02-$3.84$2.68 billion$2.70 billion
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
$1.0220.73%N/AN/A N/A
Owens & Minor, Inc. stock logo
OMI
Owens & Minor
N/AN/AN/AN/AN/A
Patterson Companies, Inc. stock logo
PDCO
Patterson Companies
$1.043.32%N/A67.53%N/A
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
N/A
4.55
4.55
Owens & Minor, Inc. stock logo
OMI
Owens & Minor
2.11
1.09
0.45
Patterson Companies, Inc. stock logo
PDCO
Patterson Companies
0.34
1.37
0.76
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
N/A
8.94
8.94

Institutional Ownership

CompanyInstitutional Ownership
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
95.84%
Owens & Minor, Inc. stock logo
OMI
Owens & Minor
98.04%
Patterson Companies, Inc. stock logo
PDCO
Patterson Companies
85.43%
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
65.32%

Insider Ownership

CompanyInsider Ownership
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
11.70%
Owens & Minor, Inc. stock logo
OMI
Owens & Minor
3.69%
Patterson Companies, Inc. stock logo
PDCO
Patterson Companies
1.90%
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
16.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
20089.14 million60.53 millionOptionable
Owens & Minor, Inc. stock logo
OMI
Owens & Minor
22,50077.26 million74.34 millionOptionable
Patterson Companies, Inc. stock logo
PDCO
Patterson Companies
7,70088.47 million86.64 millionOptionable
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
580138.24 million116.24 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Amylyx Pharmaceuticals stock logo

Amylyx Pharmaceuticals NASDAQ:AMLX

$4.90 +0.11 (+2.30%)
Closing price 04:00 PM Eastern
Extended Trading
$4.89 -0.01 (-0.10%)
As of 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Amylyx Pharmaceuticals, Inc., a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada. It is also developing AMX0114 for other neurodegenerative diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Owens & Minor stock logo

Owens & Minor NYSE:OMI

$6.50 -0.02 (-0.23%)
Closing price 03:59 PM Eastern
Extended Trading
$6.50 -0.01 (-0.15%)
As of 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Owens & Minor, Inc. is a healthcare solutions company, which engages in the product manufacturing and delivery, home health supply, and perioperative services to support care through the hospital and into the home. It operates through the Products and Healthcare Services, and Patient Direct segments. The Products and Healthcare Services segment includes medical distribution, the outsourced logistics and value-added services business, and global products, which manufacture and source medical surgical products through the production and kitting operations. The Patient Direct segment includes the home healthcare business, Byram and Apria. The company was founded by Otho O. Owens and G. Gilmer Minor in 1882 and is headquartered in Henrico County, VA.

Patterson Companies stock logo

Patterson Companies NASDAQ:PDCO

$31.33 0.00 (0.00%)
As of 04/17/2025

Patterson Companies, Inc. engages in the distribution of dental and animal health products in the United States, the United Kingdom, and Canada. The company operates through three segments: Dental, Animal Health, and Corporate segments. The Dental segment offers consumable products, including infection control, restorative materials, and instruments; basic and advanced technology and dental equipment; practice optimization solutions, such as practice management software, e-commerce, revenue cycle management, patient engagement solutions, and clinical and patient education systems. It also provides a range of related services comprising software and design services, maintenance and repair, and equipment financing. The Animal Health segment distributes biologicals, pharmaceuticals, vaccines, parasiticides, diagnostics, prescription and non-prescription diets, nutritional's, consumable supplies, equipment, and software, as well as value-added services. This segment also provides private label portfolio of products to veterinarians, producers, and retailers under the Aspen, First Companion, and Patterson Veterinary brands. The Corporate segment offers customer financing services; and sells other miscellaneous products. It serves dentists, laboratories, institutions, other healthcare professionals, veterinarians, other animal health professionals, production animal operators, and animal health product retailers. The company was formerly known as Patterson Dental Company and changed its name to Patterson Companies, Inc. in June 2004. Patterson Companies, Inc. was founded in 1877 and is headquartered in Saint Paul, Minnesota.

Vir Biotechnology stock logo

Vir Biotechnology NASDAQ:VIR

$5.19 +0.43 (+9.03%)
Closing price 04:00 PM Eastern
Extended Trading
$5.10 -0.09 (-1.71%)
As of 04:49 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Vir Biotechnology, Inc., an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; collaboration with WuXi Biologics (Hong Kong) Limited and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. The company was incorporated in 2016 and is headquartered in San Francisco, California.